Corticosteroids in management of anaphylaxis; a systematic review of evidence

C. K. LIYANAGE1, P. GALAPPATTHY1, S.L. SENEVIRATNE2,3

1Department of Pharmacology, Faculty of Medicine, University of Colombo, Sri Lanka
2Department of Surgery, Faculty of Medicine, University of Colombo, Sri Lanka
3Department of Clinical Immunology, Royal Free Hospital, London, UK
Work was carried out at Department of Pharmacology, Faculty of Medicine, University of Colombo, Sri Lanka

Key words
Anaphylaxis; emergency management; corticosteroids; prednisolone; allergy

Corresponding author
Chiranthi Kongala Liyanage
Department of Pharmacology, Faculty of Medicine, University of Colombo
25, Kinsey road, Colombo 08, Sri Lanka
Phone: +94 11 2697 483, +94 77 2330 362
Fax: +94 11 2697 483
E-mail: chiranthiliyanage@gmail.com

Doi
10.23822/EurAnnACI.1764-1489.15

Abbreviations
ED, Emergency department; IgE, Immunoglobulin E; IL-6, Interleukin 6; IL-33, Interleukin 33; PAF, Platelet activating factor; RCT, Randomized control trial; TNF α, Tumor necrosis factor α.

Introduction
Anaphylaxis is a “serious, generalized or systemic acute immunologic reaction” that is “rapid in onset and that would be fatal or life threatening” (1-3). Based on available data from international studies, the life-time prevalence of anaphylaxis has been estimated at 0.05 to 2% (4), with an estimated incidence ranging from 10 to 20/100,000 population per year (5-7). The incidence of anaphylaxis is also reportedly increasing worldwide, particularly food-induced anaphylaxis (8,9).

Anaphylaxis is brought about by direct or indirect activation of mast cells. Anaphylaxis classically involves the skin (80%), respiratory (70%), gastrointestinal (30-45%), cardiovascular (10-45%) and central nervous (10-15%) systems (2,6,10-12). Symptoms generally appear suddenly, progress over minutes to hours and increase in severity. Although only one organ system may be initially involved, symptoms will typically progress to eventually involve at least two organ systems (13,14). The diagnosis of anaphylaxis relies heavily on clinical judgment due to

Summary
As anaphylaxis is a medical emergency, there are no randomized controlled clinical trials on its emergency management. Therefore, current guidelines are mostly based on data from observational studies, animal and laboratory studies. Although epinephrine is the mainstay of recommended treatment, corticosteroids are also frequently used. This review evaluates the evidence on the use of corticosteroids in emergency management of anaphylaxis from published human and animal or laboratories studies. Thirty original research papers were found with 22 human studies and eight animal or laboratory studies. The average rate of corticosteroid use in emergency treatment was 67.99% (range 48% to 100%). Corticosteroids appear to reduce the length of hospital stay, but did not reduce revisits to the emergency department. There was no consensus on whether corticosteroids reduce biphasic anaphylactic reactions. None of the human studies had sufficient data to compare the response to treatment in different treatment groups (i.e. corticosteroids, epinephrine, antihistamines). Animal studies demonstrated that corticosteroids act through multiple mechanisms. These modulate gene expression, with effects becoming evident 4 to 24 hours after administration. A much quicker response has been detected within 5 to 30 minutes, through blockade of signal activation of glucocorticoid receptors independent of their genomic effects. Therefore, we conclude that there is no compelling evidence to support or oppose the use of corticosteroid in emergency treatment of anaphylaxis. However, based on the available data, it appears to be beneficial and there was no evidence of adverse outcomes related to the use of corticosteroids in emergency treatment of anaphylaxis.
Corticosteroids in management of anaphylaxis; a systematic review of evidence

the lack of availability of rapid diagnostic tests (13,15). Therefore, given the heterogeneity of presentation, there are widespread concerns regarding under diagnosis, under reporting and inadequate treatment of anaphylaxis and non-adherence to management guidelines (16-18).

As anaphylaxis is a medical emergency, conducting randomised control trials (RCT) on treatment of anaphylaxis is practically and ethically problematic. A Cochrane review published in 2013 concluded that there is no evidence from high quality studies for the use of steroids in the emergency management of anaphylaxis (19). The evidence base underpinning the currently recommended first-line of treatment epinephrine is also based on observational studies and extrapolated from laboratory studies. Although not as robust as evidence from RCTs, a systematic analysis of published data on other treatment modalities in the emergency management of anaphylaxis could lead to beneficial inferences.

Pathogenesis of anaphylaxis

The underlying pathogenesis of classical anaphylaxis involves IgE, synthesized in response to exposure to an allergen, becoming fixed to a high affinity receptors for IgE (FcεRI receptors) on the surface membranes of mast cells and basophils (11). On re-exposure to the same allergen, receptor-bound IgE molecules aggregate and results in cell activation. Activation of multiple tyrosine kinases (i.e. Lyn, Syk, and Fyn) with both positive and negative regulatory responses on the signal transduction cascade (20) leads to calcium influx in to the cells leading to cell degranulation (21,22). Mast cells and basophils release preformed chemical mediators and those that are synthesized de novo. Pre-formed mediators include histamine, tryptase, carboxypeptidase A, and proteoglycans. Inflammatory cytokines, such as IL-6, IL-33 (21,22) and TNF-α, a late-phase mediator are also released from mast cells as preformed mediators. Downstream activation of phopholipase A2 (PLA2), cyclooxygenases and lipoxygenases, leads to the production of arachidonic acid metabolites such as leukotrienes, prostaglandins and platelet activating factor (PAF). Furthermore, IgE enhances expression of FceRI receptors on mast cells and basophils and increases the intensity of anaphylaxis.

In addition to this, non-IgE mediated mechanisms have also been implicated in anaphylaxis. IgG mediated anaphylaxis has been reported due to triggers such as high molecular weight dextran, infusion of chimeric and therapeutic monoclonal antibodies such as infliximab (23,24). Hemodialysis, liposomal iron dextran, infusion of chimeric and therapeutic monoclonal antibodies such as infliximab have also been implicated in anaphylaxis. IgG mediated anaphylaxis has been described in some individuals in whom FceRI receptors may aggregate through autoimmune mechanisms (27). The mechanism by which certain triggers such as exercise, cold air or water exposure and radiation induce anaphylaxis is not yet fully understood. Irrespective of the initiating mechanism, mast cells and basophils play a central role in mediating an anaphylactic reaction. The release of cellular mediators leads to end-organ responses in the skin, respiratory tract, cardio-vascular system, gastrointestinal tract and perhaps the nervous system (14). Most anaphylactic reactions are uniphasic. However, additional patterns of reactions have been described i.e. delayed onset, biphasic reactions and protracted or persistent reactions (28). In biphasic reactions, the initial reaction is followed by a relatively symptom-free period and the symptoms recur, often in a more severe and refractory to therapy form (29). The exact mechanism involved in each of these patterns is not yet fully understood.

Guidelines on treatment of anaphylaxis

Currently, the recommended mainstay of therapy in the event of an anaphylaxis is epinephrine given either intramuscularly or intravenously in specialist settings (14,30-33). It counters most of the pathophysiogical processes giving rise to anaphylaxis (11,34). Second-line treatments include corticosteroids, H1- and H2-antihistamines, and bronchodilators. Unlike with epinephrine, there are differing recommendations regarding the use of glucocorticoids and other additional therapies in emergency management of anaphylaxis (35). Recommended emergency treatment of anaphylaxis according to recent guidelines is summarized in table 1.

The American (13) guidelines state that there is no place for glucocorticoids in emergency management of anaphylaxis. The British (36), European (30), Australasian (33), Canadian (37) and the World Allergy Organisation (31) guidelines recommend glucocorticoids as a second-line / adjuvant therapy after initial treatment with adrenaline and acknowledge the lack of robust evidence to support this practice (13,30,31,38). The recommended type, route, dose and duration of therapy of glucocorticoids are also varied. Prednisolone, methylprednisolone, dexamethasone and hydrocortisone administered orally, intravenously or intramuscularly are advocated in different guidelines (35). These are given as a single dose or continued for few days as a short course after the initial event (2,35,39).

Mechanism of action of glucocorticoids in anaphylaxis

The use of glucocorticoids in anaphylaxis is supported by the logical deduction of how the mechanism of action of glucocor-
<table>
<thead>
<tr>
<th>Organisation, country, year of publication, reference</th>
<th>First line of therapy, route</th>
<th>Glucocorticoids</th>
<th>Other therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>World Allergy Organization, 2015</td>
<td>Adrenaline, IM</td>
<td>Not given</td>
<td>Second or third-line: H1 antihistamines, H2-antihistamines</td>
</tr>
<tr>
<td></td>
<td></td>
<td>To prevent biphasic reactions. No effect on initial symptoms</td>
<td></td>
</tr>
<tr>
<td>Australasian Society of Clinical Immunology and Allergy (ASCIA), Australia, 2015</td>
<td>Adrenaline, IM</td>
<td>Prednisolone, Oral</td>
<td>Glucagon, metaraminol, vasopressin</td>
</tr>
<tr>
<td>European Academy of Allergy and Clinical Immunology, 2014</td>
<td>Adrenaline, IM</td>
<td>Third-line</td>
<td>Second-line: inhaled short-acting beta-2 agonists; Third-line: Oral H1- (and H2)-antihistamines</td>
</tr>
<tr>
<td>American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI), USA, 2014</td>
<td>Adrenaline, IM</td>
<td>Adjuvant, not effective in the acute management of anaphylaxis</td>
<td>glucagon, b-agonist, H1 and/or H2 antihistamines</td>
</tr>
<tr>
<td>Canadian Paediatric Society, Canada, 2010</td>
<td>Adrenaline, IM</td>
<td>Prednisone, Oral</td>
<td>second-line agents: cetirizine, diphenhydramine, ranitidine, salbutamol, glucagon</td>
</tr>
<tr>
<td>Working Group of the Resuscitation Council, UK, 2008</td>
<td>Adrenaline, IM</td>
<td>Hydrocortisone, Slow intravenous or intramuscular</td>
<td>Adjuvant therapies: salbutamol (inhaled or IV), ipratropium (inhaled), aminophylline (IV) or magnesium (IV). When initial resuscitation with adrenaline and fluids has not been successful: noradrenaline, vasopressin, metaraminol and glucagon</td>
</tr>
</tbody>
</table>

Table 1 - Summary guidelines on emergency management of anaphylaxis.
Corticosteroids counteracts the pathophysiological processes in anaphylaxis. It is also drawn from evidence of their efficacy in treatment of diseases mediated by similar immunological responses such as asthma (40,41). An illustration of the mechanism of glucocorticoids in anaphylaxis is given in figure 1.

Glucocorticoids are potent inhibitors of inflammatory processes and potent anti-allergic compounds reducing the number, maturation and activation of mast cell, which play a central role in anaphylaxis (42-44). They act through modulation of gene expression, and therefore require 4 to 6 hours for the effects to manifest (45). These anti-inflammatory effects are mediated by direct binding of the glucocorticoid / glucocorticoid receptor complex to specific elements in the promoter region of genes, or by interacting with other transcription factors such as the activating protein-1 or nuclear factor-kappa B (40,41,46). For example, in the mast cells, glucocorticoids down-regulate transcription of pro-inflammatory molecules such as cytokines, chemokines, arachidonic acid metabolites and directly regulate multiple signaling and adaptor molecules (47). These genomic effects of glucocorticoids are relatively delayed with the maximal effect being detected at 2 hours (48). Thus, seemingly little evidence supports their use in emergency management of anaphylaxis, as many aspects of glucocorticoids action were initially thought to be both time and transcription-dependent.

However, recent studies have shown that glucocorticoids also exert rapid non-genomic effects, which can be non-specific or specific (10,49,50), brought about by membrane interactions at high concentration (51) or mediated by interactions with intracellular receptors or membrane-bound receptors (52,53). In some cases, these are thought to be mediated through the classical steroid receptor that functions as a ligand-activated transcription factor. Two animal studies have shown that glucocorticoids have detectable inhibitory effects on anaphylaxis within 5 to 30 minutes, mostly through blockade of these glucocorticoid.

**Figure 1 - Pathogenesis of anaphylaxis and mechanism of action of glucocorticoids.**
Figure 2 - Summary of search strategy and results.

Records identified through database searching (n = 289)

Additional records identified through other sources (n = 26)

Records screened (n = 315)

Full text articles assessed for eligibility (n = 40)

Records excluded (n = 257)
- Records of anaphylaxis due to corticosteroids - 147
- Other Reasons (e.g. premedication with corticosteroids for prevention of anaphylaxis) - 110

Studies included in qualitative synthesis (n = 30)

Human studies included in qualitative synthesis (n = 22)

Animal studies included in qualitative synthesis (n = 8)

Search strategy

Searched libraries included Pubmed / Medline from inception to March 2016. Additional references were found through cross-references from articles and reviews. The key words used included anaphylaxis, allergy, hypersensitivity, corticosteroids, glucocorticoids, steroids, dexamethasone, hydrocortisone, prednisolone. Human and animal studies on glucocorticoids for management of allergy or anaphylaxis in peer-review journals were included. The search was refined by language (English).

Results

The original search found 289 articles in PubMed (figure 2). Twenty-six additional articles were identified through other sources. However, 147 of these were found to be on anaphylaxis due to corticosteroids. There were 28 relevant original research papers reviewed with 22 human studies and 8 animal or laboratory studies. The human studies included 19 retrospective cohort studies, one cross sectional descriptive study and two prospective cohort studies.

Use of corticosteroids in anaphylaxis: human studies

The relevant papers on human studies are summarised in table 2. The rate of corticosteroid use in emergency treatment of anaphylaxis varied from 48% to 100% with an average of 67.99%.
Biphasic anaphylactic reactions were reported in approximately 2.2% to 8.7% of patients reporting to emergency departments (56,57). A study conducted in a tertiary care hospital in Canada has found that those who develop biphasic reactions are less likely to have received epinephrine or corticosteroids during emergency management (58). However, three other studies have not found a significant difference in emergency treatment with either epinephrine or steroids in those with or without biphasic reactions (56,59). There is some evidence suggesting that the length of hospital stay tends to be shorter in those treated with corticosteroids for anaphylaxis (60). However, it has not been found to reduce the revisits to the emergency department with anaphylaxis or other unrelated causes (61). None of the human studies had sufficient data to comment on the response

<table>
<thead>
<tr>
<th><strong>Table 2</strong> - Use of corticosteroids in anaphylaxis; human studies.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author, country, year</strong></td>
</tr>
<tr>
<td>-------------------------</td>
</tr>
<tr>
<td>Jiang et al., China, 2016</td>
</tr>
<tr>
<td>Michelson KA et al., USA, 2015</td>
</tr>
<tr>
<td>Grunau BE et al., Canada, 2015</td>
</tr>
<tr>
<td>Ko BS et al., Korea, 2015</td>
</tr>
</tbody>
</table>

Cont. overleaf
<table>
<thead>
<tr>
<th>Author, country, year</th>
<th>Study group</th>
<th>Study type</th>
<th>Percentage treated with steroids</th>
<th>Study objective</th>
<th>Findings relevant to cortisosteroids</th>
<th>Study weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asia Y et al., Canada, 2014</td>
<td>37,730 patients with anaphylaxis visiting the emergency department of a tertiary care center</td>
<td>Retrospective cohort study</td>
<td>68.1</td>
<td>Demographic characteristics, suspected triggers and management of anaphylaxis</td>
<td>Higher percentage of severe reactions (71.4%) are treated with steroids compared to mild (50.0%) and moderate (67.8%) reactions.</td>
<td>The outcome of treatment is not assessed</td>
</tr>
<tr>
<td>Worm et al., Germany, 2014</td>
<td>3333 cases of anaphylaxis over a 3 year period from 10 European countries</td>
<td>Retrospective record analysis of one line data registry</td>
<td>60.4</td>
<td>Epidemiology, symptomatology, triggers, treatment</td>
<td>No additional data provided on steroid use or outcomes</td>
<td>There was no comparison of the outcome of different treatment modalities</td>
</tr>
<tr>
<td>Manuyakorn W et al., Thailand, 2013</td>
<td>160 children (aged 3 months to 18 years) diagnosed with anaphylaxis</td>
<td>Retrospective cohort study</td>
<td>93</td>
<td>Epidemiology, symptomatology, treatment practices</td>
<td>92.3% of patients with uniphasic reactions and 93.3% of patients with biphasic reactions are treated with systemic corticosteroids (P &gt; 0.05)</td>
<td>Retrospective records analysis. The outcome of treatment is not stated</td>
</tr>
<tr>
<td>Rappo et al. Australia, 2013</td>
<td>34 cases anaphylaxis due to tick bite presenting an emergency department</td>
<td>Retrospective cohort study</td>
<td>97%</td>
<td>Epidemiology, symptomatology, course of illness, treatment</td>
<td>71% were discharged on oral prednisolone. One (4.1%) of them developed a biphasic reaction</td>
<td>Retrospective medical record review with a small sample size. There is no comparison of the outcome among the treatment groups</td>
</tr>
<tr>
<td>Veizir et al., Turkey, 2013</td>
<td>96 patients presenting to ED</td>
<td>Prospective cohort study</td>
<td>80.2</td>
<td>Epidemiology, symptomatology, triggers, treatment</td>
<td>Only 44.4% received epinephrine</td>
<td></td>
</tr>
<tr>
<td>Hompes S. et al., Germany, 2011</td>
<td>1281 anaphylactic reactions voluntarily reported through an online registry</td>
<td>Cross sectional descriptive study</td>
<td>85</td>
<td>Demography, symptomatology, course of anaphylaxis, treatment</td>
<td>Corticosteroids were given intravenously in 50%, orally in 29%, and through rectal application in 6%.</td>
<td></td>
</tr>
<tr>
<td>Hoffer et al., Israel, 2011</td>
<td>92 children admitted to a single medical center with the diagnosis of anaphylaxis</td>
<td>Retrospective cohort study</td>
<td>85</td>
<td>Epidemiology, symptomatology, course of illness, laboratory findings, treatment, concurrent illnesses</td>
<td>Only 72% were treated with epinephrine. 75% received antihistamines</td>
<td>The outcome of the different treatment is not analyzed</td>
</tr>
<tr>
<td>Orhan et al., Turkey, 2011</td>
<td>224 cases of anaphylaxis reported in 137 children</td>
<td>Retrospective cohort study</td>
<td>83.5</td>
<td>Epidemiology, symptomatology, course of illness, treatment practices</td>
<td>Only 32.3% received epinephrine</td>
<td></td>
</tr>
<tr>
<td>Sole et al., Brazil, 2011</td>
<td>634 patients from 15 Latin American countries and Portugal with severe allergic reactions</td>
<td>Cross sectional descriptive study</td>
<td>80.5</td>
<td>Epidemiology, symptomatology, triggers, course of illness, treatment, outcome</td>
<td>There is no comparison of outcome of different treatment</td>
<td></td>
</tr>
</tbody>
</table>

Cont. overleaf
<table>
<thead>
<tr>
<th>Author, country, year</th>
<th>Study group</th>
<th>Study type</th>
<th>Percentage treated with steroids</th>
<th>Study objective</th>
<th>Findings relevant to cortisteroids</th>
<th>Study weakness</th>
</tr>
</thead>
<tbody>
<tr>
<td>Russell et al., USA, 2010</td>
<td>103 patients with the diagnosis of anaphylaxis visiting the emergency department</td>
<td>Retrospective descriptive study</td>
<td>79</td>
<td>Epidemiology, symptomatology, triggers, course of illness, treatment, outcome</td>
<td>Only 56% received intramuscular epinephrine</td>
<td></td>
</tr>
<tr>
<td>De Swert et al., Belgium, 2008</td>
<td>64 cases of anaphylaxis</td>
<td>Prospective cohort study</td>
<td>45.6</td>
<td>Epidemiology, clinical features, triggers, treatment practices, outcome</td>
<td>Only 9.1% received epinephrine</td>
<td>Small sample size</td>
</tr>
<tr>
<td>Ellis AK &amp; Day JH, Canada, 2007</td>
<td>134 patients with anaphylaxis (in-patients and outpatients) at a tertiary care center</td>
<td>Retrospective cohort study</td>
<td>Presence of biphasic reaction, course of illness, treatment</td>
<td>Biphasic reactors received less epinephrine and tended to receive less corticosteroid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaeta et al., USA, 2007</td>
<td>12.4 million allergy-related emergency department visits with 1% being coded as anaphylaxis over a 9 year period</td>
<td>Retrospective cohort study</td>
<td>50</td>
<td>Epidemiology, symptomatology, triggers, treatment</td>
<td>Corticosteroid use increased during the study period (22% to 50%; P &lt; 0.001) Epinephrine use was infrequent and declining (19% to 7%; P = 0.04)</td>
<td></td>
</tr>
<tr>
<td>Clark et al., USA, 2005</td>
<td>617 with anaphylaxis presenting to the ED with in a one year period</td>
<td>Retrospective cohort study</td>
<td>49</td>
<td>Epidemiology, symptomatology, triggers, treatment</td>
<td>Only 7% were treated with epinephrine</td>
<td></td>
</tr>
<tr>
<td>Clark et al., USA, 2004</td>
<td>A random sample of 678 charts of patients who presented with food allergy</td>
<td>Retrospective cohort study</td>
<td>48</td>
<td>Epidemiology, symptomatology, triggers, treatment</td>
<td>Only 16% were treated with epinephrine</td>
<td></td>
</tr>
<tr>
<td>Brown et., Australia, 2001</td>
<td>162 patients with acute allergic reactions and 142 patients with anaphylaxis</td>
<td>Retrospective cohort study</td>
<td>78</td>
<td>Epidemiology, clinical features, possible triggers, treatment practices, outcome</td>
<td>Only 40% received epinephrine</td>
<td>A retrospective record analysis</td>
</tr>
<tr>
<td>Lee JM &amp; Greenes DS, USA, 2000</td>
<td>106 inpatient (108 anaphylaxis episodes)</td>
<td>Retrospective cohort study</td>
<td>Symptomatology, course of illness, treatment</td>
<td>Patients with or without biphasic reactions did not differ significantly in the incidence of initial epinephrine use, initial steroid use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stewart &amp; Ewan, 1996</td>
<td>9 patients with anaphylaxis admitted to ED</td>
<td>Retrospective cohort study</td>
<td>77.8</td>
<td>Epidemiology, symptomatology, triggers, treatment practices, outcome</td>
<td>A patient record analysis with a small sample size</td>
<td></td>
</tr>
</tbody>
</table>
to treatment in different treatment groups (i.e. corticosteroids, epinephrine, antihistamines).

**Use of corticosteroids in anaphylaxis; animal and laboratory studies**

The findings of the relevant papers are summarized in table 3. The animal models used included guinea pigs (62-64) and mice (48,53,65,66). One other study was conducted using A549 human adenocarcinoma cell line (52). Most investigated the effect of pretreatment with glucocorticoids. The postulated mechanisms of action include action through modulation of gene expression occurring 4 to 24 hours after treatment with glucocorticoids (48,65) and blockade of signal activation of glucocorticoid receptors independent of its genomic effects (52,53). The latter response has been detectable within 5 to 30 minutes (52,53). Interestingly, prednisolone has been found to inhibit passive cutaneous anaphylaxis in a biphasic manner at 8-12 and 24 hours (48).

**Discussion**

Anaphylaxis is an acute immunologic reaction due to direct or indirect activation of mast cells. Prompt definitive management can be life saving, and any delays may result in a fatal outcome. Irrespective of the trigger, management of anaphylaxis is the same for all patients. Although epinephrine is clearly recommended as the first line treatment for management of anaphylaxis, human studies reviewed here revealed that usage of epinephrine either during pre-hospital or emergency care varies widely from 7-70% (12). This could be due to over-prudent hesitancy to administer epinephrine with the fear of serious adverse effects. Conversely, there is a lower threshold to initiate glucocorticoid therapy in patients with anaphylaxis. Despite the lack of any strong recommendations, 45-97% of the patients receive glucocorticoids in emergency management of anaphylaxis (16,39,67,68). Some multicenter trials have demonstrated that corticosteroids are still being administered as the first-line therapy instead of epinephrine (17,18,39).

When considering the pathogenesis of anaphylaxis and the mechanism of action of glucocorticoids, it becomes evident that glucocorticoids have a theoretical benefit in treatment of anaphylaxis. For many years, glucocorticoids were thought to act through nuclear receptors by modulating gene expression, hence having delayed onset of action. However, recent advancements have demonstrated that glucocorticoids induce a rapid anti-inflammatory effect by a non-genomic mechanism, acting through membrane-bound or cytosolic receptors. Laboratory studies have demonstrated a detectable response in as little as 5 minutes from the point of administration.

Most cases of anaphylaxis resolved after initial treatment. One to 20% will develop a biphasic reaction, a delayed recurrence of illness occurring hours after improvement of the symptoms (59,61,69). There are multiple factors that have been described to be associated with biphasic reactions including under-treatment and delay in treatment (58,59). The World Allergy Organisation recommends the administration of glucocorticoids to prevent such biphasic reactions, and states that there are no or minimal effects on initial symptoms (31). This is supported by laboratory studies, which demonstrate that prednisolone inhibits passive cutaneous anaphylaxis in a biphasic manner. However, except for one retrospective cohort study, none of the other human studies found that glucocorticoids lower the incidence or prevents the progression of symptoms. Although observational studies reveal that those with more severe reactions are more likely to be given corticosteroids, there is no conclusive evidence to infer that early administration of corticosteroids prevents progression of symptoms (56,70). Additional benefits such as shortening the length of hospital stay and reducing the need to repeated epinephrine injections have also been attributed to glucocorticoid therapy in anaphylaxis. A major limitation in the human studies included in this review is the lack of data on the outcome of patients by the treatment received in the emergency department to make a meaningful comparison between treatment groups.

**Conclusions**

Corticosteroids are often used in the management of anaphylaxis and sometimes used as a first-line therapy instead of adrenaline, despite the lack of compelling evidence and guidelines recommending their use only as an adjuvant therapy. There are no randomised or quasi-randomised trials providing support to this practice. Nevertheless, the pathophysiological basis of anaphylaxis and the mechanism of action of glucocorticoids, particularly the recent evidence of the rapid non-genomic effects provide a rational basis for using corticosteroids in the emergency treatment of anaphylaxis. However, there is no concrete evidence to support or oppose the use of corticosteroids in emergency management of anaphylaxis, particularly as short-term use of glucocorticoids is seldom associated with serious adverse effects (71). Therefore, based on the animal / laboratory studies and human studies reviewed, we conclude that use of glucocorticoids along with administration of epinephrine in the emergency management of anaphylaxis is rational and may be beneficial. Although RCT may not being plausible, more evidence is needed on treatment and treatment outcomes through at least prospective cohort studies. These could provide valid data to evaluate the definitive place of glucocorticoids in the emergency management of anaphylaxis.
### Table 3 - Use of corticosteroids in anaphylaxis; animal studies.

<table>
<thead>
<tr>
<th>Author, Country, Year</th>
<th>Animal model</th>
<th>Study objective</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obiri et al., USA, 2011</td>
<td>PEP +/- mice</td>
<td>Effect of glucocorticoids in PEST-domain-enriched tyrosine phosphatase (PEP) in bone marrow derived mast cells</td>
<td>Glucocorticoid increased PEP expression in mast cells and only partially inhibited anaphylaxis. Glucocorticoid potently inhibited anaphylaxis when combined with the PEP inhibitor</td>
</tr>
<tr>
<td>Croxtall et al., 2000</td>
<td>A549 human adenocarcinoma cell line</td>
<td>Assess the rapidity changes induced by dexamethasone and the mechanism of action</td>
<td>Dexamethasone, inhibits the activation of AA release by EGF by a mechanism without the involvement of the suppression of cPLA2 expression. Blockade of signal activation by dexamethasone was detectable within 5 to 10 mins. The dose-dependence of this inhibitory effect of dexamethasone was the same at 5 min and 3h. The rapid effect of glucocorticoids is mediated by occupation of glucocorticoid receptor</td>
</tr>
<tr>
<td>Miura et al., Japan, 1992</td>
<td>Rats with PCA and cutaneous reactions caused by histamine serotonin and leukotriene C4 elicited at the same time</td>
<td>Inhibitory mechanisms of glucocorticoids in immediate hypersensitivity reactions - passive cutaneous anaphylaxis (PCA) mediated by IgE antibodies and cutaneous reactions caused by histamine serotonin and leukotriene C4</td>
<td>Hydrocortisone, prednisolone and dexamethasone, inhibited all these reactions significantly. Hydrocortisone given 1-4 and 12 hours inhibited PCA significantly. Maximum inhibition observed at 2 hours. Maximum inhibitions of histamine, serotonin and LTC4-induced cutaneous reactions observed at 2 hours. Prednisolone inhibited PCA biphasically at 24 and 8-12 hours. Dexamethasone inhibited PCA persistently between 2 to 12 hours and maximally at 4 hours</td>
</tr>
<tr>
<td>Rong &amp; Zhao-Gui, Changsha, 1989</td>
<td>Guinea pigs heart</td>
<td>The protective effect of H1 &amp; H2 antagonists, adenosine and hydrocortisone on cardiac anaphylaxis</td>
<td>Hydrocortisone delayed the onset of arrhythmias and significantly reduced the duration of arrhythmias. When histamine receptor antagonists are used with hydrocortisone, a good protective effect can be achieved</td>
</tr>
<tr>
<td>Guhlmann et al., Germany, 1989</td>
<td>Guinea pigs suffering from anaphylactic shock</td>
<td></td>
<td>There was a lack of effect of dexamethasone on anaphylactic LTC4 generation in vivo</td>
</tr>
<tr>
<td>Inagaki et al., Japan, 1987</td>
<td>Rats injected with Ascaris suum extract serum</td>
<td>Effect of hydrocortisone, prednisolone and dexamethasone on IgE antibody-mediated homologous passive cutaneous anaphylaxis (PCA)</td>
<td>Injection sites were evaluated 30 minutes after injection. Glucocorticoids inhibited the PCA dose-dependently. They also inhibited the skin reactions caused by histamine, serotonin and LTC4 and reduced vascular permeability</td>
</tr>
<tr>
<td>King et al., USA, 1984</td>
<td>Outbred Wistar rats</td>
<td>Effect of glucocorticoids on intestinal anaphylaxis in the rat</td>
<td>Manifestations of anaphylaxis were abolished in rats previously treated with corticosteroids 48 and 24 before injection. This was associated with depletion of RMCP-II and of MMC from the intestinal mucosa detectable at 4-24 hours after treatment</td>
</tr>
<tr>
<td>Andersson &amp; Brattsand, Sweden, 1982</td>
<td>Guinea-pigs sensitized to two ovalbumin regimens</td>
<td>Effect of budesonide and hydrocortisone on histamine release from anaphylactically-shocked chopped lung fragments</td>
<td>Budesonide pretreatment reduced the capacity of anaphylactically-challenged chopped lung tissue to release histamine</td>
</tr>
</tbody>
</table>
References


Corticosteroids in management of anaphylaxis; a systematic review of evidence


